Key Benefits of Cagrilintide
 Mechanism of Action
Mimics amylin, a hormone that:
Promotes satiety
Slows gastric emptying
Suppresses post-meal glucagon
Targets hypothalamic centers to reduce hunger and caloric intake.
Clinical Trial Highlights
Monotherapy Results
REDEFINE 1 (Phase 3):
Average 11.8% body weight reduction over 68 weeks
Compared to 2.3% with placebo
~31% of participants achieved ≥15% weight loss